TuHURA BIOSCIENCES, INC./NV: 10-Q filed 2015-02-12
What TuHURA BIOSCIENCES, INC./NV reported in its quarterly report filed 2015-02-12 (fiscal Q2 2015): 18 published measures, 57 facts as tagged in accession 0001013762-15-000152.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-02-12
- Fiscal period
- fiscal Q2 2015
- Accession
- 0001013762-15-000152 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TuHURA BIOSCIENCES, INC./NV filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 4,128,378 | USD | |
| At 2014-06-30 | 5,003,910 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 2,041,827 | USD | |
| At 2014-06-30 | 4,123,431 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 2,086,551 | USD | |
| At 2014-06-30 | 880,479 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 3,958,439 | USD | |
| At 2014-06-30 | 4,759,711 | USD | |
| At 2013-12-31 | 4,136,803 | USD | |
| At 2013-06-30 | 6,282,992 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 1,076,759 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 2,399,120 | USD | 184 |
| 2013-10-01 to 2013-12-31 | 865,976 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -5,928,256 | USD | 184 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 37,798,183 | shares | 92 |
| 2014-07-01 to 2014-12-31 | 37,125,074 | shares | 184 |
| 2013-10-01 to 2013-12-31 | 31,523,732 | shares | 92 |
| 2013-07-01 to 2013-12-31 | 31,477,137 | shares | 184 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 37,798,183 | shares | 92 |
| 2014-07-01 to 2014-12-31 | 37,125,074 | shares | 184 |
| 2013-10-01 to 2013-12-31 | 31,523,732 | shares | 92 |
| 2013-07-01 to 2013-12-31 | 41,742,401 | shares | 184 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 0.03 | USD/shares | 92 |
| 2014-07-01 to 2014-12-31 | 0.06 | USD/shares | 184 |
| 2013-10-01 to 2013-12-31 | 0.03 | USD/shares | 92 |
| 2013-07-01 to 2013-12-31 | -0.19 | USD/shares | 184 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 0.03 | USD/shares | 92 |
| 2014-07-01 to 2014-12-31 | 0.06 | USD/shares | 184 |
| 2013-10-01 to 2013-12-31 | 0.03 | USD/shares | 92 |
| 2013-07-01 to 2013-12-31 | 0 | USD/shares | 184 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | 260,510 | USD | 184 |
| 2013-07-01 to 2013-12-31 | 626,279 | USD | 184 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-12-31 | -2,091 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -2,044 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -4,073 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 294,186 | USD | |
| At 2014-06-30 | 299,866 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -1,268,398 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -2,385,025 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -1,202,242 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -2,503,845 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -612,169 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -1,283,796 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -566,060 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -1,126,295 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 38,580,306 | shares | |
| At 2014-06-30 | 35,992,343 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 21,178 | USD | |
| At 2014-06-30 | 21,178 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -656,229 | USD | 92 |
| 2014-07-01 to 2014-12-31 | -1,101,229 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -636,182 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -1,377,550 | USD | 184 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -191,639 | USD | 92 |
| 2014-07-01 to 2014-12-31 | 14,095 | USD | 184 |
| 2013-10-01 to 2013-12-31 | -336,266 | USD | 92 |
| 2013-07-01 to 2013-12-31 | -8,432,101 | USD | 184 |
Inspect the source
- Entity
- TuHURA BIOSCIENCES, INC./NV / CIK 0001498382
- Captured
- 2026-09-20T09:11:11.339Z
- SEC response SHA-256
cbfb2cda3307f7af300be1fc56e9d85ca5186f16e46a189d675574c95ee74f5c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001498382.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))